Clinical Trials

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, in order to classify patients into post-consolidation treatment groups. On the second part of this study, patients will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.

Welter, Stacy L

welter.stacy@marshfieldresearch.org

(715) 221-6492

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.

Kidwell, Anna

kidwell.anna@marshfieldresearch.org

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI  54868

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI  54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI  54548

MMC - River Region at Stevens Point

,   

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI  54476

This phase III trial tests the addition of sodium thiosulfate to standard of care chemotherapy and radiation therapy in treating patients with low or average risk medulloblastoma (a type of cancer in the brain). Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Although treatment for newly diagnosed average-risk and low-risk medulloblastoma is generally effective at treating the cancer, there are still concerns about the side effects of such treatment. Side effects are unintended problems that arise due to treatment such as learning difficulties, lower amounts of hormones, hearing problems, or other problems in performing daily activities. Patients with medulloblastoma often receive treatment with chemotherapy drugs including cisplatin. Cisplatin may cause hearing loss as a side effect. Previous studies with sodium thiosulfate have shown that it may help reduce or prevent hearing loss caused by cisplatin. This study looks at adding sodium thiosulfate to standard treatment for medulloblastoma (radiation therapy and chemotherapy, including cisplatin) to find out if it reduces hearing loss.

Welter, Stacy L

welter.stacy@marshfieldresearch.org

(715) 221-6492

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). Open thoracic surgery is a type of surgery done through a single larger incision (like a large cut) that goes between the ribs, opens up the chest, and removes the cancer. Thoracoscopy is a type of chest surgery where the doctor makes several small incisions and uses a small camera to help with removing the cancer. This trial is being done evaluate the two different surgery methods for patients with osteosarcoma that has spread to the lung to find out which is better.

Welter, Stacy L

welter.stacy@marshfieldresearch.org

(715) 221-6492

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

This phase III trial compares the effect of vinorelbine with vincristine, dactinomycin, and cyclophosphamide (VAC) followed by vinorelbine and cyclophosphamide versus VAC followed by vinorelbine and cyclophosphamide for the treatment of high risk rhabdomyosarcoma. Chemotherapy drugs, such as vinorelbine, vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vinorelbine and VAC may kill more tumor cells. Adding maintenance therapy (vinorelbine and cyclophosphamide) after VAC therapy, with or without vinorelbine, may help get rid of the cancer and/or lower the chance that the cancer comes back.

Welter, Stacy L

welter.stacy@marshfieldresearch.org

(715) 221-6492

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.

Humphrey, Logan J

humphrey.logan@marshfieldresearch.org

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI  54548

MMC - River Region at Stevens Point

,   

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI  54476

This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with mantle cell lymphoma.

Bulgrin, Angela M

BULGRIN.ANGELA@marshfieldresearch.org

(715) 221-7261

Marshfield Medical Center

611 Saint Joseph Ave

Marshfield, WI  54449

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI  54868

MC - Chippewa Falls Center

2655 CTY HWY I

CHIPPEWA FALLS, WI  54729

MC - Wausau Center

2727 PLAZA DRIVE

WAUSAU, WI  54401

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI  54701

MMC - Ladysmith

906 College Ave W

Ladysmith, WI  54848

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI  54548

MMC - River Region at Stevens Point

,   

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI  54476

This phase Ib/II clinical trial studies the side effects and best dose of venetoclax and how well it works when given together with vincristine liposomal in treating patients with T-cell or B-cell acute lymphoblastic leukemia that has come back or does not respond to treatment. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vincristine liposomal, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax together with vincristine liposomal may work better in treating patients with acute lymphoblastic leukemia.

Huotari, Cressa L

huotari.cressa@marshfieldresearch.org

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms.

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI  54868

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI  54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI  54548

MMC - River Region at Stevens Point

,   

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI  54476

C-14 is a prospective multicenter study that will enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer (CRC), who have sufficient residual formalin-fixed paraffin-embedded (FFPE) tissue available from the primary resection for research testing and are willing to provide FFPE and serial whole blood samples for circulating tumor DNA(ctDNA) analysis.

Kidwell, Anna

kidwell.anna@marshfieldresearch.org

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI  54868

MMC - Eau Claire

2116 Craig Rd

Eau Claire, WI  54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI  54548

MMC - River Region at Stevens Point

,   

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI  54476